| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b012ccfd2fa9e27c506c64cb338e0af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37b36726b8c2d3a2fe627ab8caf1e052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3b4f2ef8f062dcde3a2b7cd81748472 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y503-04001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 |
| filingDate |
2022-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d94c1b4f76d33c47b02ac09dff4f36bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_371ae7f3f11d0cc9d5c4ad58688e349e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a8a5b876bfb14d9cf2daf6c09815794
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_faa78d9f1e9ea8432f0198ef934fcd4b |
| publicationDate |
2022-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022218998-A1 |
| titleOfInvention |
Methods for treating hepatitis b and d virus infection |
| abstract |
In the present invention, a combination of computational and experimental approaches was used to unravel the main determinants of hepatitis B virus (HBV) membrane fusion process. They discovered that ERp57 is a host factor critically involved in triggering HBV fusion and infection. Then, through modelling approaches, they uncovered a putative allosteric cross-strand disulfide (CSD) bond in the HBV S glycoprotein and demonstrate that its stabilization could prevent membrane fusion. These results underscore a membrane fusion mechanism that could be triggered by ERp57, allowing a thiol/disulfide exchange reaction to occur and regulate isomerization of a critical CSD, which ultimately leads to the exposition of the fusion peptide. Finally, targeting ERp57 with a pharmacological agent or with oligo antisense approach in a infection assay with human cell line (with HDV and HBV particle) induced a strongly decrease the level of HBV and HDV infection. Furthermore, these results were confirmed in vivo in a liver humanized mice (HuHep mice) and inhibition of ERp57 with a pharmacological agent prevent HBV propagation and infection. Accordingly, the present invention relates to an inhibitor of ERp57 for use in the treatment of Hepatitis B virus (HBV) or Hepatitis B virus (HBV) infection said inhibitor said ERp57 inhibitor inhibit the virus entry by membrane fusion. |
| priorityDate |
2021-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |